Karolinska Development invests SEK 7.5 million to support BOOST Pharma's continued development of BT-101 towards Phase 3

Core Insights - Karolinska Development AB has invested SEK 7.5 million in BOOST Pharma's financing round, which totals SEK 15 million, aimed at advancing the clinical development of BT-101 for osteogenesis imperfecta [1][3][4] Company Overview - BOOST Pharma is a clinical-stage biopharmaceutical company focused on developing BT-101, a mesenchymal stem cell therapy for infants with osteogenesis imperfecta, a condition that leads to fragile bones and frequent fractures [2][3] - The financing will help BOOST Pharma accelerate its clinical program and work towards providing the first disease-modifying therapy for osteogenesis imperfecta [2] Clinical Development - Following positive results from the Phase 2 BOOSTB4 study, which showed a reduction in fracture rate of over 75% in children treated with BT-101, BOOST Pharma is preparing for a pivotal Phase 3 trial [3] - The BOOSTB4 trial demonstrated that BT-101 was safe and well-tolerated [3] Investment and Ownership - Karolinska Development holds a 14% ownership stake in BOOST Pharma, reflecting its commitment to supporting the development of innovative therapies [4]